Skip to main content
Erschienen in: International Ophthalmology 6/2013

01.12.2013 | Original Paper

Surgical removal of subfoveal choroidal neovascularization in pathologic myopia: a 12-year follow-up study

verfasst von: R. Hera, C. Chiquet, J. P. Romanet

Erschienen in: International Ophthalmology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to review the 12-year visual outcomes of patients who underwent surgical removal for subfoveal choroidal neovascularization (CNV) attributable to pathologic myopia. This retrospective study included 14 patients, with a mean age of 45.8 years, high myopia (>6 D) and classic subfoveal CNV. They were treated with pars plana vitrectomy and surgical removal of CNV. All patients were followed up every 3 months for 2 years, with visual acuity (VA), fundus examination, and fluorescein angiography and then every year for 5 years. Ten patients underwent a final visit with VA and fundus examination after a minimum 12-year follow-up. The main outcome measurement was VA and the secondary outcome measurement was the lesion size. After 12 years of follow-up, the mean VA did not significantly change over time, with a mean gain of 0.22 logMAR at 1 year, and 0.18, 0.12 and 0.05 at 2, 5 and 12 years, respectively. The anatomical evolution was characterized by a significant enlargement of the lesion size at 5 years. This study showed that final VA after surgical treatment with 12 years of follow-up was poor, due to the significant CNV scar enlargement over time. These results should prompt a prospective randomized study of other medical treatments, particularly anti-vascular endothelial growth factor therapy.
Literatur
1.
Zurück zum Zitat Tabandeh H, Flynn HW Jr, Scott IU, Lewis ML, Rosenfeld PJ, Rodriguez F, Rodriguez A, Singerman LJ, Schiffman J (1999) Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 106:2063–2067PubMedCrossRef Tabandeh H, Flynn HW Jr, Scott IU, Lewis ML, Rosenfeld PJ, Rodriguez F, Rodriguez A, Singerman LJ, Schiffman J (1999) Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 106:2063–2067PubMedCrossRef
2.
Zurück zum Zitat Miller DG, Singerman LJ (2001) Natural history of choroidal neovascularization in high myopia. Curr Opin Ophthalmol 12:222–224PubMedCrossRef Miller DG, Singerman LJ (2001) Natural history of choroidal neovascularization in high myopia. Curr Opin Ophthalmol 12:222–224PubMedCrossRef
3.
Zurück zum Zitat Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M (2003) Myopic choroidal neovascularization a 10-year follow-up. Ophthalmology 110:1297–1305PubMedCrossRef Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M (2003) Myopic choroidal neovascularization a 10-year follow-up. Ophthalmology 110:1297–1305PubMedCrossRef
4.
Zurück zum Zitat V.I.P. (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial—vip report no. 1. Ophthalmology 108:841–852CrossRef V.I.P. (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial—vip report no. 1. Ophthalmology 108:841–852CrossRef
5.
Zurück zum Zitat Yamamoto I, Rogers A, Reichel E, Yates P, Duker J (2007) Intravitreal bevacizumab (avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91:157PubMedCrossRef Yamamoto I, Rogers A, Reichel E, Yates P, Duker J (2007) Intravitreal bevacizumab (avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91:157PubMedCrossRef
6.
Zurück zum Zitat Chan W, Lai T, Liu D, Lam D (2007) Intravitreal bevacizumab (avastin) for myopic choroidal neovascularization six-month results of a prospective pilot study. Ophthalmology 114:2190–2196PubMedCrossRef Chan W, Lai T, Liu D, Lam D (2007) Intravitreal bevacizumab (avastin) for myopic choroidal neovascularization six-month results of a prospective pilot study. Ophthalmology 114:2190–2196PubMedCrossRef
7.
Zurück zum Zitat Ruiz-Moreno J, de la Vega C (2001) Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 85:1041PubMedCrossRef Ruiz-Moreno J, de la Vega C (2001) Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br J Ophthalmol 85:1041PubMedCrossRef
8.
Zurück zum Zitat Thomas M, Dickinson J, Melberg N, Ebanez H, Dhaliwal R (1994) Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 101:1384–1396PubMedCrossRef Thomas M, Dickinson J, Melberg N, Ebanez H, Dhaliwal R (1994) Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 101:1384–1396PubMedCrossRef
9.
Zurück zum Zitat Uemura A, Thomas M (2000) Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol 118:344PubMedCrossRef Uemura A, Thomas M (2000) Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol 118:344PubMedCrossRef
10.
Zurück zum Zitat Bottoni F, Perego E, Airaghi P, Cigada M, Ortolina S, Carlevaro G, De Molfetta V (1999) Surgical removal of subfoveal choroidal neovascular membranes in high myopia. Graefes Arch Clin Exp Ophthalmol 237:573–582PubMedCrossRef Bottoni F, Perego E, Airaghi P, Cigada M, Ortolina S, Carlevaro G, De Molfetta V (1999) Surgical removal of subfoveal choroidal neovascular membranes in high myopia. Graefes Arch Clin Exp Ophthalmol 237:573–582PubMedCrossRef
11.
Zurück zum Zitat Hera R, Mouillon M, Gonzalvez B, Millet J, Romanet J (2001) Chirurgie des néovaisseaux choroïdiens rétrofovéolaires du sujet myope fort: Etude rétrospective sur 17 cas. J Fr Ophtalmol 24:716–723PubMed Hera R, Mouillon M, Gonzalvez B, Millet J, Romanet J (2001) Chirurgie des néovaisseaux choroïdiens rétrofovéolaires du sujet myope fort: Etude rétrospective sur 17 cas. J Fr Ophtalmol 24:716–723PubMed
12.
Zurück zum Zitat Glacet-Bernard A, Benyelles N, Dumas S, Haddad W, Voigt M, Razavi S, Roquet W, Coscas G, Soubrane G (2007) Photodynamic therapy vs limited macular translocation in the management of subfoveal choroidal neovascularization in pathologic myopia: a two-year study. Am J Ophthalmol 143:68–76PubMedCrossRef Glacet-Bernard A, Benyelles N, Dumas S, Haddad W, Voigt M, Razavi S, Roquet W, Coscas G, Soubrane G (2007) Photodynamic therapy vs limited macular translocation in the management of subfoveal choroidal neovascularization in pathologic myopia: a two-year study. Am J Ophthalmol 143:68–76PubMedCrossRef
13.
Zurück zum Zitat Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—vip report no. 3. Ophthalmology 110:667–673PubMedCrossRef Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—vip report no. 3. Ophthalmology 110:667–673PubMedCrossRef
14.
Zurück zum Zitat Parodi MB, Da Pozzo S, Ravalico G (2007) Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia. Acta Ophthalmol Scand 85:50–54PubMedCrossRef Parodi MB, Da Pozzo S, Ravalico G (2007) Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia. Acta Ophthalmol Scand 85:50–54PubMedCrossRef
15.
Zurück zum Zitat Cohen S (2009) Anti-vegf drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 29:1062PubMedCrossRef Cohen S (2009) Anti-vegf drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 29:1062PubMedCrossRef
16.
Zurück zum Zitat Lalloum F, Souied E, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N (2010) Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 30(3):399–406PubMedCrossRef Lalloum F, Souied E, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N (2010) Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 30(3):399–406PubMedCrossRef
17.
Zurück zum Zitat Pruett R (1994) Pathologic myopia. In: Albert DM, Jakobiec FA (eds) Principles and practice of ophthalmology, vol 2. WB Saunders, Philadelphia, p 878–882 Pruett R (1994) Pathologic myopia. In: Albert DM, Jakobiec FA (eds) Principles and practice of ophthalmology, vol 2. WB Saunders, Philadelphia, p 878–882
18.
Zurück zum Zitat Adelberg D (1995) PRIORE D: Surgery for subfoveal membranes in myopia, angioid streaks, and other disorders. Retina 15:198PubMedCrossRef Adelberg D (1995) PRIORE D: Surgery for subfoveal membranes in myopia, angioid streaks, and other disorders. Retina 15:198PubMedCrossRef
19.
Zurück zum Zitat Essex R, Tufail A, Bunce C, Aylward G (2007) Two-year results of surgical removal of choroidal neovascular membranes related to non-age-related macular degeneration. Br Med J 91:649 Essex R, Tufail A, Bunce C, Aylward G (2007) Two-year results of surgical removal of choroidal neovascular membranes related to non-age-related macular degeneration. Br Med J 91:649
20.
Zurück zum Zitat Hamelin N, Glacet-Bernard A, Brindeau C, Mimoun G, Coscas G, Soubrane G (2002) Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am J Ophthalmol 133:530–536PubMedCrossRef Hamelin N, Glacet-Bernard A, Brindeau C, Mimoun G, Coscas G, Soubrane G (2002) Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am J Ophthalmol 133:530–536PubMedCrossRef
Metadaten
Titel
Surgical removal of subfoveal choroidal neovascularization in pathologic myopia: a 12-year follow-up study
verfasst von
R. Hera
C. Chiquet
J. P. Romanet
Publikationsdatum
01.12.2013
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 6/2013
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-013-9761-3

Weitere Artikel der Ausgabe 6/2013

International Ophthalmology 6/2013 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.